Stock Scorecard
Stock Summary for AnaptysBio Inc (ANAB) - $16.36 as of 12/9/2023 1:37:24 AM EST
Total Score
8 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ANAB
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ANAB
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ANAB
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for ANAB
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for ANAB
Financial Details for ANAB
Company Overview |
|
---|---|
Ticker | ANAB |
Company Name | AnaptysBio Inc |
Country | USA |
Description | AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2023 |
Next Earnings Date | 2/28/2024 |
Stock Price History |
|
Last Day Price | 16.36 |
Last Day Price Updated | 12/9/2023 1:37:24 AM EST |
Last Day Volume | 0 |
Average Daily Volume | N/A |
52-Week High | 32.44 |
52-Week Low | 13.36 |
Last Price to 52 Week Low | 22.46 % |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 57.56 |
Sector PE | 62.37 |
5-Year Average PE | -12.10 |
Free Cash Flow Ratio | 1.05 |
Industry Free Cash Flow Ratio | 10.37 |
Sector Free Cash Flow Ratio | 31.15 |
Current Ratio Most Recent Quarter | 10.92 |
Total Cash Per Share | 15.54 |
Book Value Per Share Most Recent Quarter | 4.53 |
Price to Book Ratio | 3.61 |
Industry Price to Book Ratio | 4.33 |
Sector Price to Book Ratio | 19.59 |
Price to Sales Ratio Twelve Trailing Months | 29.06 |
Industry Price to Sales Ratio Twelve Trailing Months | 10.29 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.61 |
Share Statistics |
|
Total Shares Outstanding | 26,575,200 |
Market Capitalization | 434,770,272 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Dividend King? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00 % |
5-Year Dividend Payments Count | 0 |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00 % |
Annual Earnings Growth | -122.72 % |
Reported EPS 12 Trailing Months | -5.42 |
Reported EPS Past Year | -4.49 |
Reported EPS Prior Year | -4.57 |
Net Income Twelve Trailing Months | -147,821,000 |
Net Income Past Year | -128,724,000 |
Net Income Prior Year | -57,796,000 |
Quarterly Revenue Growth YOY | 156.60 % |
5-Year Revenue Growth | 32.40 % |
Balance Sheet |
|
Total Cash Most Recent Quarter | 413,047,000 |
Total Cash Past Year | 441,241,000 |
Total Cash Prior Year | 548,097,000 |
Net Cash Position Most Recent Quarter | 413,047,000 |
Net Cash Position Past Year | 441,241,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 1,375,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 262,103,000 |
Total Stockholder Equity Prior Year | 356,428,000 |
Total Stockholder Equity Most Recent Quarter | 120,383,000 |
Options |
|
Put/Call Ratio | 0.00 |
Has Options | Options Chain |
Liquidity Rating | None |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.32 |
MACD Signal | -0.67 |
20-Day Bollinger Lower Band | 13.90 |
20-Day Bollinger Middle Band | 17.68 |
20-Day Bollinger Upper Band | 21.45 |
Beta | -0.27 |
RSI | 56.19 |
50-Day SMA | 20.63 |
200-Day SMA | 23.24 |
System |
|
Modified | 12/10/2023 5:29:50 AM EST |